CERTAIN RELATIONSHIPS AND RELATED-PARTY TRANSACTIONS
Other than as disclosed below, from January 1, 2019 to the present, there have been no transactions, and there are currently no proposed transactions, in
which the amount involved exceeds $120,000 to which we or any of our subsidiaries was (or is to be) a party and in which any director, director nominee, executive officer, holder of more than 5% of our capital stock, or any immediate family member
of or person sharing the household with any of these individuals, had (or will have) a direct or indirect material interest, except for payments set forth under Proposal No. 1 Election of Class II Directors and Executive
Compensation above.
Insider Participation in 2019 Offering
Entities affiliated with Vivo Capital, LLC purchased an aggregate of (i) 24,500 shares of Series A convertible voting preferred stock (that
converted into 1,856,118 shares of our common stock in January 2020), (ii) Series A warrants to purchase 1,855,873 shares of common stock, and (iii) Series B warrants to purchase 612,436 shares of common stock in
our November 2019 offering at a combined purchase price of $1,000.00 per unit, which is the same public offering price at which units were sold to all investors in the offering. Subsequent to the offering, Dr. Gaurav Aggarwal, who is a managing
director of Vivo Capital LLC, was appointed to our Board of Directors on November 22, 2019.
Entities affiliated with Longitude Capital purchased an
aggregate of (i) 19,500 shares of Series A convertible voting preferred stock (that converted into 1,477,320 shares of our common stock in January 2020), (ii) Series A warrants to purchase 1,477,125 shares of
common stock, and (iii) Series B warrants to purchase 487,451 shares of common stock in our November 2019 offering at a combined purchase price of $1,000.00 per unit, which is the same public offering price at which units were sold to
all investors in the offering. Subsequent to the offering, Dr. Josh Richardson, who is a managing director of Longitude Capital, was appointed to our Board of Directors on November 22, 2019.
Entities affiliated with OrbiMed Advisors LLC purchased an aggregate of (i) 19,500 shares of Series A convertible voting preferred stock (that
converted into 1,477,320 shares of our common stock in January 2020), (ii) Series A warrants to purchase 1,477,124 shares of common stock, and (iii) Series B warrants to purchase 487,450 shares of common stock in
our November 2019 offering at a combined purchase price of $1,000.00 per unit, which is the same public offering price at which units were sold to all investors in the offering. Subsequent to the offering, Dr. Mona Ashiya, who is a partner of
OrbiMed Advisors, LLC, was appointed to our Board of Directors on November 22, 2019.
Entities affiliated with Abingworth Bioventures VII, LP
purchased an aggregate of (i) 11,500 shares of Series A convertible voting preferred stock (that converted into 871,240 shares of our common stock in January 2020), (ii) Series A warrants to purchase 871,125 shares
of common stock, and (iii) Series B warrants to purchase 287,471 shares of common stock in our November 2019 offering at a combined purchase price of $1,000.00 per unit, which is the same public offering price at which units were sold
to all investors in the offering. Subsequent to the offering, Dr. Andrew Sinclair, who is a partner and portfolio manager of Abingworth LLP, was appointed to our Board of Directors on November 22, 2019.
Policies and Procedures for Related-Party Transactions
We have adopted a written related-person transactions policy that provides that our executive officers, directors, nominees for election as a director,
beneficial owners of more than 5% of our common stock, and any members of the immediate family of the foregoing persons, are not permitted to enter into a material related-person transaction with us without the review and approval of our Audit
Committee, or a committee composed solely of independent directors in the event it is inappropriate for our Audit Committee to review such transaction due to a conflict of interest. The policy provides that any request for us to enter into a
transaction with an executive officer, director, nominee for election as a director, beneficial owner of more than 5% of our common stock or
32